Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma.
View/ Open
Date
2018-08-20ICR Author
Author
Pender, A
Davis, EJ
Chauhan, D
Messiou, C
Al-Muderis, O
Thway, K
Fisher, C
Zaidi, S
Miah, A
Judson, I
van der Graaf, W
Keedy, VL
Benson, C
Jones, RL
Type
Journal Article
Metadata
Show full item recordAbstract
The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following failure of first-line anthracycline-based chemotherapy, several salvage options are available. We reviewed the safety and efficacy of gemcitabine/docetaxel chemotherapy in two tertiary oncology centres. We identified patients treated with gemcitabine/docetaxel between 2004 and 2016 in a UK and a US oncology centre using retrospective pharmacy and medical records. Treatment response, toxicity and outcome data were collected. Twenty one patients were treated with gemcitabine/docetaxel, the majority as a second- or third-line treatment for metastatic disease. The response rate was 5% with a median progression-free survival of 2 months (95% CI 1.3-3.7). Toxicities reported were as expected for this chemotherapy combination. Treatment was not discontinued due to toxicity. Gemcitabine/docetaxel chemotherapy shows little efficacy in synovial sarcoma and should not be offered to this patient group outside a clinical trial context.
Subject
Humans
Sarcoma, Synovial
Deoxycytidine
Antineoplastic Agents
Antimetabolites, Antineoplastic
Antineoplastic Combined Chemotherapy Protocols
Treatment Outcome
Palliative Care
Retrospective Studies
Adult
Middle Aged
Female
Male
Young Adult
Research team
Clinical and Translational Sarcoma
Sarcoma Clinical Trials (R Jones)
Lung Cancer Group
Targeted Therapy
Language
eng
Date accepted
2018-08-12
License start date
2018-08-20
Citation
Medical oncology (Northwood, London, England), 2018, 35 (10), pp. 131 - ?
Publisher
HUMANA PRESS INC